Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis

Allocca, M.; Crosignani, A.; Gritti, A.; Ghilardi, G.; Gobatti, D.; Caruso, D.; Zuin, M.; Podda, M.; Battezzati, P. M.
December 2006
Gut;Dec2006, Vol. 55 Issue 12, p1795
Academic Journal
Background: Hypercholesterolaemia often occurs in primary biliary cirrhosis (PBC) as a result of chronic cholestasis, but whether these patients are exposed to greater cardiovascular risk is unknown. Aim: To establish whether hypercholesterolaemia is associated with subclinical atherosclerosis in PBC. Patients: 103 consecutive patients with PBC (37 with total cholesterol ⩾6.21 mmol/l) and 37 controls with hypercholesterolaemia, and 141 matched controls with normocholesterolaemia. Methods: Ultrasound imaging of carotid artery to determine intima-media thickness (IMT) and stenosis. Results: Controls with hypercholesterolaemia had higher IMT and prevalence of carotid stenosis compared with patients with hypercholesterolaemic PBC (mean (SD) 0.850 (0.292) mm v 0.616 (0.137) mm, pc<0.001; 43% v 19%, pc=0.129) who, in turn, were similar to the 66 patients with normocholesterolaemic PBC (0.600 (0.136) mm; 5%). Compared with subjects with normocholesterolaemia, controls with hypercholesterolaemia, but not patients with hypercholesterolaemic PBC, had an increased risk of raised IMT (odds ratio (OR) 5.4, 95% confidence interval (CI) 2.5 to 11.9, p<0.001; and 0.7, 0.3 to 2.0, or carotid stenosis (8.2, 3.4 to 20, p<0.001 and 2.5, 0.9 to 6.9, p=0.07.5). In PBC, compared with younger patients without hypertension, the risk of increased IMT was OR (CI) 3.1(0.6 to 17; p =0.192) in patients with hypertension or old age, but not hypercholesterolaemia, and 4.6 (0.8 to 27; p=0.096) in patients who also had hypercholesterolaemia. The corresponding figures for risk of stenosis were 3.6 (0.4 to 36; p=0.277) and 15.8 (1.8 to 141; p=0.014). Conclusions: Hypercholesterolaemia is not consistently associated with subclinical atherosclerosis in PBC, but should be treated if other risk factors for cardiovascular disease are also present. The search for factors that may protect patients with hypercholesterolaemic PBC against atherosclerosis should be encouraged.


Related Articles

  • Statin Discontinuation in High-Risk Patients: A Systematic Review of the Evidence. Sandoval, Yessica-Haydee Gomez; Braganza, Michael V.; Daskalopoulou, Stella S. // Current Pharmaceutical Design;11/11/2011, Vol. 17 Issue 33, p3669 

    Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD), the leading cause of death worldwide. Since the late 1980s, statins have emerged as effective lipid-lowering therapies and are now widely used to protect against and slow the progression of CVD and cerebrovascular...

  • Effect of a multivitamin preparation supplemented with phytosterol on serum lipids and infarct size in rats fed with normal and high cholesterol diet. Csont, Tamás; Sárközy, Márta; Sz¿cs, Gerg¿; Sz¿cs, Csilla; Bárkányi, Judit; Bencsik, Péter; Gáspár, Renáta; Földesi, Imre; Csonka, Csaba; Kónya, Csaba; Ferdinandy, Péter // Lipids in Health & Disease;2013, Vol. 12 Issue 1, p1 

    Background Although complex multivitamin products are widely used as dietary supplements to maintain health or as special medical food in certain diseases, the effects of these products were not investigated in hyperlipidemia which is a major risk factor for cardiovascular diseases. Therefore,...

  • Pitavastatin: a guide to its use in hypercholesterolaemia and mixed dyslipidaemia. Lyseng-Williamson, Katherine A.; Duggan, Sean T. // Drugs & Therapy Perspectives;Sep2012, Vol. 28 Issue 9, p5 

    Several questions and answers are presented on the topic of the use of the statin drug Pitavastatin to treat hypercholesterolemia and mixed dyslipidemia, including efficacy for patients at increased risk for cardiovascular disease, possible interactions with other drugs, and potential side effects.

  • Utilidad de las técnicas de imagen y biomarcadores en la predicción del riesgo cardiovascular en pacientes con enfermedad renal crónica en España: Proyecto NEFRONA. Junyent, M.; Martínez, M.; Borrás, M.; Betriu, A.; Coll, B.; Craver, L.; Marco, M. P.; Sarró, F.; Valdivielso, J. M.; Fernández, E. // Nefrologia;Feb2010, Vol. 30 Issue 1, p119 

    Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of traditional risk factors to fully account for the elevated CVD risk, mainly due...

  • Model-based assessment of dynamic arterial blood volume flow from ultrasound measurements. Leguy, C. A. D.; Bosboom, E. M. H.; Hoeks, A. P. G.; Van de Vosse, F. N. // Medical & Biological Engineering & Computing;Jun2009, Vol. 47 Issue 6, p641 

    To assess in clinical practice arterial blood volume flow (BVF) from ultrasound measurements, the assumption is commonly made that the velocity profile can be approximated by a quasi-static Poiseuille model. However, pulsatile flow behaviour is more accurately described by a Womersley model. No...

  • Tailoring the Implementation of New Biomarkers Based on Their Added Predictive Value in Subgroups of Individuals. van Giessen, A.; Moons, K. G. M.; de Wit, G. A.; Verschuren, W. M. M.; Boer, J. M. A.; Koffijberg, H. // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Background: The value of new biomarkers or imaging tests, when added to a prediction model, is currently evaluated using reclassification measures, such as the net reclassification improvement (NRI). However, these measures only provide an estimate of improved reclassification at population...

  • Relationship between components of the metabolic syndrome and job strain using a brief job stress questionnaire (BJSQ). Kawada, Tomoyuki // International Archives of Occupational & Environmental Health;Aug2013, Vol. 86 Issue 6, p725 

    A letter to the editor is presented in response to the article "The role of psychosocial stress at work for the development of cardiovascular diseases: a systematic review," by E. M. Backe and colleagues in the 2012 issue.

  • Dietary fat intake and prevention of cardiovascular disease. Hooper, Lee; Summerbell, Carolyn D.; Higgins, Julian P. T.; Thompson, Rachel L.; Capps, Nigel E.; Smith, George Davey; Riemersma, Rudolph A.; Ebrahim, Shah // BMJ: British Medical Journal (International Edition);03/31/2001, Vol. 322 Issue 7289, p757 

    Assesses the effect of reduction or modification of dietary fat intake on total and cardiovascular mortality and cardiovascular morbidity. Methods; Results; Conclusion that there is a small but potentially important reduction in cardiovascular risk with reduction or modification of dietary fat...

  • Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.  // BMC Cardiovascular Disorders;2012, Vol. 12 Issue 1, p41 

    The article presents the findings of a systematic review conducted on examining whether prescription stimulants increase the risk of adverse cardiovascular events. It discusses the methodology of the research. It reveals that the association between prescription stimulant use and adverse...

  • Urinary Sodium and Cardiovascular Disease Risk: Informing Guidelines for Sodium Consumption. Whelton, Paul K. // JAMA: Journal of the American Medical Association;11/23/2011, Vol. 306 Issue 20, p2262 

    The article offers insights on a study which examined the association between sodium intake and cardiovascular disease (CVD) risk published in this issue. It notes that the study was able to confirm a J-shaped relationship between sodium excretion and CVD risk. It questions the validity of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics